Treatment Options for BCR After Local Therapy for Prostate Cancer
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
- Biochemical relapse is a heterogenous disease state and is likely related to tumor biology
- Classically, patients who have received a radical prostatectomy may be candidates for salvage radiation therapy with or without hormone therapies
- Patients who initially received primary radiation therapy may be candidates for salvage radical prostatectomy or hormone therapy
- In a previous study, patients in this space were essentially cured following treatment with docetaxel plus estramustine and ADT
- This trial, presented at the 2014 Genitourinary Cancers Symposium, aimed to determine the benefit of docetaxel plus bevacizumab and ADT
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
